Veradigm

Business Challenge

The vaccines that helped curtail the COVID-19 pandemic included a wide range of challenges and the need for analytics. The accelerated approval process left patients and regulators with long-term safety questions, including potential vaccine-associated myocarditis questions, such as: How common is it? How severe is it? Securing answers to these questions is challenging due to the low incidence of myocarditis and poor clinical coding data with few of the cases reported accurately.

Analytics Solution

Veradigm has fostered a collaboration with the American College of Cardiology and Moderna to tackle vaccine-associated myocarditis head-on. This effort has required assembling a collection of real-world data from multiple sources to construct a patient’s complete health care journey with potential vaccine-associated myocarditis. This requires incorporating multiple disparate data sources and bringing all elements together into a single data easy-to-use platform by leveraging passive and active data collection. On this digital platform, a panel of cardiologists can interrogate the data, communicate with the primary managing health care practitioner and gather additional insights.

Impact

Veradigm’s comprehensive solution to characterizing vaccine-associated myocarditis is a valuable resource for answering questions about vaccine-associated myocarditis and launching new research, along with testing future hypotheses. This is a scientific advancement and novel application of analytics to myocarditis and is a substantial step forward in evaluating the benefits and risks of COVID-19 vaccination efforts. This analytic platform can serve as a basis for additional work concerning COVID-19 vaccine safety and better understanding the underlying disease.